Immune reconstitution inflammatory syndrome after initiation of highly active anti-retroviral therapy in HIV/AIDS

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 3, 2010, Pages 301-304

  Mohanty, Kailash ^a  

^a DARLINGTON MEMORIAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CORTICOSTEROID; EFAVIRENZ; FLUCONAZOLE; FLUOROURACIL; ISONIAZID; LOPINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; RIFABUTIN; RIFAMPICIN; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CRYPTOCOCCAL MENINGITIS; CYTOMEGALOVIRUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE SYSTEM; LUMBAR PUNCTURE; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM TUBERCULOSIS; PNEUMOCYSTIS CARINII; REVIEW; TUBERCULOSIS; VARICELLA ZOSTER VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME;

EID: 77952602505     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.62981     Document Type: Review

References (17)

1. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): A review of common infectious manifestations and treatment options. AIDS Res Ther 2007;4:9.
2. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of TB following ART in patients with AIDS. Am J Respir Crit Med 1998;158:157-61.
3. Shankar EM, Vignesh R, Murugavel KG, Balakrishnan P, Sekar R, Lloyd CA, et al. IRIS in association with HIV/AIDS and TB: Views over hidden possibilities. AIDS Res Ther 2007;4:29-42.
4. Pires A, Nelson M, Pozniak AL, Fisher M, Gazzard B, Gotch F, et al. Mycobaterial IRIS in HIV 1 infection after ART associated with specific T cell responses: Beneficial effect of IL-2 and GM-csf immunotherapy. J Immune Based Ther Vaccines 2005;3:7.
5. British HIV Association (BHIVA) guidelines on TB/HIV infection, 2005. Available from: Http://Www.bhiva.org. [cited in 2005].
6. HIV treatment bulletin, treatment access. HIV I-base, third floor east. Vol. 10. London: Thrale House; 2009. p. 28.
7. French MA, Mallal SA, Dawkins RL. Zidovudine induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV infected patients. AIDS 1992;6:1293-7.
8. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000;1:107-15.
9. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and Risk factors for IRIS in an ethnically diverse HIV 1 infected cohort. Clin Infect Dis 2006;42:418-27.
10. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after Initiation of successful HAART. Clin Infect Dis 2002;35:128-33.
11. Martineuk F, Rao SD, Rea TH, Glickman MS, Rom JW, Cabrera A, et al. Leprosy as IRIS in HIV positive persons Emerg Infect Dis 2007;13:1438.
12. Mehta S, Padhir B, Shah B. Leprosy presenting as IRIS. Indian J STDs 2008;29:96-7.
13. Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA. Miliary TB with paradoxical expansion of intracranial tuberculomas complicating HIVinfection in a patient receiving HAART. Clin Infect Dis 1998;26:1008-9.
14. Longmore M, Wilkinson I, Torok E. Oxford handbook of clinical medicine. 5th ed. Oxford: Oxford University Press; 2008.
15. Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with initiation of cart. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:122-8.
16. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. CMV retinitis after initiation of HAART. Lancet 1997;349:1443-5.
17. Bartlett JG, Joel EG. Medical management of HIV infection. Baltimore, Maryland USA: John Hopkins University; 2003.